Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Ikkou Group CoTSE:3353 +0.17%63 EV-to-EBIT is 7.43 as of Aug. 27, 2026, which is 24% below its 10-year median of 9.76. GuruFocus rates TSE:3353 with a GF Score™ of 63/100 and a GF Value™ of 円3,602.01 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 450 Conglomerates companies, Medical Ikkou Group Co ranks better than 71.11% on this metric.
Medical Ikkou Group Co (TSE:3353) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medical Ikkou Group Co's Enterprise Value for the quarter that ended in Feb. 2026 was 円16,383 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Ikkou Group Co's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was 円2,127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Medical Ikkou Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Ikkou Group Co EV-to-EBIT vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medical Ikkou Group Co's EV-to-EBIT falls into.
Medical Ikkou Group Co's current Enterprise Value is 円15,818 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Ikkou Group Co's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was 円2,127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Ikkou Group Co (TSE:3353) has a EV-to-EBIT of 7.43 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medical Ikkou Group Co and its competitors. This is 24% below median its historical median of 9.76. Over the past decade, Medical Ikkou Group Co's EV-to-EBIT has ranged from 5.68 to 21.65. According to the industry distribution chart, Medical Ikkou Group Co ranks #130 out of 450 companies in the Conglomerates industry, placing it in the top 28.9%.
Is Medical Ikkou Group Co's EV-to-EBIT too high?
Medical Ikkou Group Co's current EV-to-EBIT of 7.43 is 24% below median its 10-year median of 9.76. Over the past 10 years, this metric has ranged from a low of 5.68 to a high of 21.65. The Conglomerates industry median EV-to-EBIT is 11.52. Medical Ikkou Group Co's value of 7.43 is 35.5% below this industry median. Based on the distribution chart, Medical Ikkou Group Co ranks #130 out of 450 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Medical Ikkou Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's EV-to-EBIT compare to MMM and HON?
According to the Conglomerates industry distribution chart, Medical Ikkou Group Co ranks #130 out of 450 companies for EV-to-EBIT. This puts Medical Ikkou Group Co in the upper half of its industry. The industry median EV-to-EBIT is 11.52. Medical Ikkou Group Co's value of 7.43 is 35.5% below this benchmark. Historically, Medical Ikkou Group Co's own EV-to-EBIT has ranged from 5.68 to 21.65 over the past decade. While the company's 10-year median is 9.76 vs. the industry median of 11.52, Medical Ikkou Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Conglomerates company?
The median EV-to-EBIT among Conglomerates companies is 11.52, based on 450 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Ikkou Group Co's current EV-to-EBIT of 7.43 is 35.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medical Ikkou Group Co and its competitors. For the Conglomerates industry, the median EV-to-EBIT is 11.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Ikkou Group Co's current EV-to-EBIT is 7.43, which is 24% below median its own 10-year median of 9.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,602.01, compared to a current price of 円2,900.00 — trading 19.5% below its estimated fair value. The current EV-to-EBIT is 7.43, which is 24% below median its 10-year median of 9.76 and 35.5% below the Conglomerates industry median of 11.52. Medical Ikkou Group Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current EV-to-EBIT is 7.43 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued.
The current stock price of 円2,900.00 is trading 19.5% below its estimated GF Value™ of 円3,602.01.
GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.
Key valuation signals for TSE:3353:
EV-to-EBIT: 7.43 (24% below median its 10-year median of 9.76)
GF Value™: 円3,602.01 vs. price of 円2,900.00 (19.5% below fair value)
Industry Position: 35.5% below the Conglomerates median (#130 of 450)
No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
63GF Score
Get the complete analysis for TSE:3353
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3353 has been successfully added to your 
